What is a stock summary page? Click here for an overview.
Business Description
Eagle Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US2697961082
Share Class Description:
EGRX: Ordinary SharesCompare
Compare
Traded in other countries / regions
EGRX.USA1E6.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-02-12Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.46 | |||||
| 9-Day RSI | 53.57 | |||||
| 14-Day RSI | 54 | |||||
| 3-1 Month Momentum % | 17.35 | |||||
| 6-1 Month Momentum % | 91.67 | |||||
| 12-1 Month Momentum % | -72.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -3.64 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1.87 | |||||
| PE Ratio without NRI | 0.36 | |||||
| EV-to-EBIT | 2.12 | |||||
| EV-to-EBITDA | 1.35 | |||||
| EV-to-Revenue | 0.29 | |||||
| Earnings Yield (Greenblatt) % | 47.17 | |||||
| FCF Yield % | -42.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:EGRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eagle Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 257.551 | ||
| EPS (TTM) ($) | 0.91 | ||
| Beta | 1.21 | ||
| 3-Year Sharpe Ratio | -0.7 | ||
| 3-Year Sortino Ratio | -0.89 | ||
| Volatility % | 148.23 | ||
| 14-Day RSI | 54 | ||
| 14-Day ATR ($) | 0.409369 | ||
| 20-Day SMA ($) | 1.529 | ||
| 12-1 Month Momentum % | -72.88 | ||
| 52-Week Range ($) | 0.0025 - 6.37 | ||
| Shares Outstanding (Mil) | 12.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eagle Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eagle Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eagle Pharmaceuticals Inc Frequently Asked Questions
What is Eagle Pharmaceuticals Inc(EGRX)'s stock price today?
The current price of EGRX is $1.70. The 52 week high of EGRX is $6.37 and 52 week low is $0.00.
When is next earnings date of Eagle Pharmaceuticals Inc(EGRX)?
The next earnings date of Eagle Pharmaceuticals Inc(EGRX) is 2025-05-15 Est..
Does Eagle Pharmaceuticals Inc(EGRX) pay dividends? If so, how much?
Eagle Pharmaceuticals Inc(EGRX) does not pay dividend.
Guru Commentaries on OTCPK:EGRX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers